Damora Therapeutics, Inc. (DMRA) › Operating Cash FlowDamora Therapeutics, Inc. (DMRA) — Operating Cash FlowAnnual figures by fiscal year, from SEC filings.2019: -$19.33M2020: -$38.20M2021: -$52.31M2022: -$42.93M2023: -$36.91M2024: -$18.62M2025: -$6.73M-$6.73M2019Operating Cash Flow (USD)2025Fiscal YearOperating Cash FlowChange YoY2025-$6.73M+63.9%2024-$18.62M+49.5%2023-$36.91M+14.0%2022-$42.93M+17.9%2021-$52.31M-36.9%2020-$38.20M-97.7%2019-$19.33M—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsCapital ExpendituresShares OutstandingDividends Per Share